News: Arena Pharmaceuticals Initiates Phase 1 Clinical Trial Program of APD791 for the Treatment of Arterial Thrombosis. Genetic Engineering News - Bi

News: Arena Pharmaceuticals Initiates Phase 1 Clinical Trial Program of APD791 for the Treatment of Arterial Thrombosis. Genetic Engineering News - Biotechnology from Bench to Business: "SAN DIEGO, July 18 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it initiated dosing in a Phase 1 clinical trial evaluating APD791, Arena's orally administered, internally discovered drug candidate intended for the treatment of arterial thrombo-embolic diseases. This Phase 1 trial is planned to enroll up to 72 healthy adult volunteers and is primarily intended to evaluate the safety and tolerability of single ascending doses of APD791. In addition, the trial will also evaluate the pharmacokinetics and pharmacodynamics of APD791."